Tandem Diabetes Care announced that real-world data supports its t:slim X2 insulin pump with Control-IQ technology.
Data from the ongoing real-world Control-IQ observational (CLIO) study demonstrating immediate and sustained benefits in a diverse cohort of participants was presented at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans.
“Our Control-IQ technology continues to be a great equalizer for people with insulin-intensive diabetes, as we consistently see positive clinical and quality-of-life improvement with its use, regardless of age, ethnicity, or prior therapy,” Tandem VP and Medical Director Dr. Jordan Pinsker said in a news release. “This evidence increases our motivation to bring new advances in technology to benefit people living with diabetes worldwide.”
RELATED: Real-world data backs Medtronic’s next-gen MiniMed 780G insulin pump
An analysis of a multi-ethnic adult cohort consisting of 1,306 participants with type 1 diabetes demonstrated significant improvements in diabetes-specific quality of life, satisfaction with insulin delivery device, and reduction in diabetes-related burden over 12 months with Control-IQ technology. All ethnic cohorts experienced Psychosocial benefits, Tandem said, while all participants using the system also noted significantly improved quality of sleep.
Tandem also shared data from an analysis of 1,045 adult CLIO patients that assessed relationships between ethnicity, baseline HbA1c, Glucose Management Indicator (GMI) and sensor time in range. The cohort included Asian, Black/African American, White, and Hispanic/Latino/Spanish participants and GMI at study end reflected glycemic improvements for all participants, with Black/African American participants demonstrating a clinically relevant 0.7% overall reduction.
Real-world evidence from a study of baseline HbA1c and GMI derived from sensor data in 1,107 adults using Control-IQ technology for 12 consecutive months demonstrated significant glycemic improvements, regardless of prior therapy modality.
Multiple daily injection users with relatively high HbA1c values initiating Control-IQ technology showed dramatic and sustained glycemic improvements, Tandem said, while previous pump users also experienced immediate and sustained imporvements.
“Demonstrating that our technology benefits ethnically diverse groups, irrespective of previous therapy modality, is critical to fulfilling our mission to improve the lives of people living with diabetes worldwide,” Tandem VP of Behavioral Sciences Steph Habif said. “As a global leader in insulin therapy management, we strive to provide diabetes care solutions that work equally well across all people living with diabetes, and the data presented at this conference is evidence of our success toward this goal.”
